Definium Therapeutics Announces Topline Results From Phase 3 Voyage Study Of DT120 ODT In Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints

뉴스 본문을 불러오고 있어요.

Definium Therapeutics Announces Topline Results From Phase 3 Voyage Study Of DT120 ODT In Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints | 웨이프 WAPE

Definium Therapeutics Announces Topline Results From Phase 3 Voyage Study Of DT120 ODT In Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints

기사 요약

관련 종목

댓글 —